Portal Diabetes has received the US Food and Drug Administration (FDA) breakthrough device designation for its implantable insulin pump system, known as the Portal Pump. It has also initiated a Phase ...

Investing.com - Mizuho raised its price target on Tandem Diabetes Care (NASDAQ:TNDM) to $22 from $21 while maintaining a Neutral rating on Thursday. The stock currently trades at $18.52, having surged ...

CEO John Sheridan stated, "2025 was a defining year for Tandem, where we surpassed the milestone of $1 billion in sales while delivering on our mission to provide new innovations, improved outcomes ...

Earnings Call Insights: Tandem Diabetes Care, Inc. (TNDM) Q4 2025 CEO John Sheridan stated, "2025 was a defining year for Tandem, where we surpassed the milestone of $1 billion in sales while ...